Cadrenal Therapeutics Inc【CVKD】株式ニュース

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form 8-K - Current report

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for...

Form 8-K - Current report

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global...

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

New high-value indication for Phase 3-ready asset with data intended to support clinical development and...

Form 8-K - Current report

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with...

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage...

Form 8-K - Current report

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

ihubstockmover 6日前

$CVKD - Selection highlights the clinical value potential of Cadrenal's first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT)

First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals

Phase-3 ready and addresses a peak $2 billion annual revenue potential in the HIT market
https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-selection-cad-120000124.html

👍️0

ihubstockmover 6日前

$CVKD Breaking News : Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-selection-cad-120000124.html

👍️0

ihubstockmover 1週前

$CVKD - announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation.

The announcement comes ahead of the BIO International Convention, June 22–25, 2026, in San Diego, California. Cardenal's executive leadership team will highlight this rare pediatric initiative and its Phase 3-ready CAD-1005 platform during one-on-one partnering meetings with global and regional pharmaceutical companies.

👍️0

ihubstockmover 2週前

$CVKD Cadrenal Therapeutics is planning to seek U.S. FDA Rare Pediatric Disease Designation for tecarfarin to treat children with Kawasaki disease who develop coronary artery aneurysms and need chronic oral anticoagulation. The company highlights a dual-track portfolio: CAD-1005 as a first-in-class 12-LOX inhibitor for critical care, and tecarfarin for regional and rare indications.

https://www.stocktitan.net/sec-filings/CVKD/8-k-cadrenal-therapeutics-inc-reports-material-event-2b43569d6ba6.html

👍️0

ihubstockmover 2週前

$CVKD News Out - Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html

👍️0

ihubstockmover 2週前

$CVKD #NASDAQ Cadrenal Therapeutics Advances CAD-1005 Multi-Indication Strategy

👍️ 1

resx18 2月前

Sir .. so you own no shares .. but are warning people not to make money trading stocks that go up? You have lost me Sir.

👍️0

resx18 2月前

Great 2 days for $CVKD !

👍️0

PEACHMAN 2月前

Sir I have never owned one share ..Just warning people

👍️0

PEACHMAN 2月前

This POS stock was much higher 6 months ago

6 months
-6.51
-50.90%
12.79
13.75
4.21
50,544
7.711
1 year
-10.22
-61.94%
16.50
17.00
4.21
39,168
9.6532
3 years
-13.67
-68.52%
19.95
47.10
4.21
121,825
16.4101
5 years
-79.37
-92.67%
85.65
101.25
4.21
130,181
20.9088

$CVKD Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-end-of-phase-2-meeting-with-the-fda-ng39svqvc9he.html

👍️ 1 🧐 1

Golden Cross 2月前

$CVKD Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Our lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Our broader pipeline includes tecarfarin, a Phase 3-ready oral vitamin K antagonist for the treatment of patients with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral, clinical-stage Factor XIa inhibitor designed for use in acute hospital settings.
https://marketwirenews.com/stock/cvkd/?utm_source=ads-top-cvkd

👍️0

Golden Cross 2月前

$CVKD Life Sciences Virtual Investor Forum – Cadrenal Therapeutics, Inc.
📺 https://www.youtube.com/watch?v=Bxqk97A9SIg

👍️0

Golden Cross 2月前

$CVKD Think we can see $6+ today!

👍️0

Golden Cross 2月前

$CVKD Strong start today +7.5%

$CVKD Ten Reasons Why Your Need to Look at Cadrenal Therapeutics
https://marketwirenews.com/stock/cvkd/?utm_source=ads-top-cvkd

$CVKD Steady Uptrend From Recent Lows.. Looking for the uptrend to continue here!

👍️0

JettaR 11月前

Watch out for this pump and dumper

👍️0

pumper_stumper 11月前

It looks like the same paid promoters that frantically pumped CBDW just before it hit a new all time low today, have been hired and have been active here for 2 months. This is "only" down about 15% in that time, but they probably haven't yet cashed out of their shares to get their payday.

Look for many many reposts from them of old news, in their feeble attempt to draw interest.

If you don't know that this a bad sign for the stock, you'll maybe eventually learn that it is!

Tecarfarin has been evaluated in 11 clinical trials in over 1.000 subjects: 269 patients were treated for at least 6 months and 129 patients were treated for one year or more.

In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well tolerated in both healthy adult subjects and patients with ESKD.

Good DD post:
https://www.reddit.com/r/pennystocks/s/PHz4s0TzdG

👍️0

resx18 12月前

Tecarfarin is Phase 3-ready with a positive safety profile.

We have established that tecarfarin has a well-established and reversible mechanism of action and demonstrated that tecarfarin’s elimination from the body was not affected by severe kidney dysfunction.

Tecarfarin has been evaluated in 11 clinical trials in over 1.000 subjects: 269 patients were treated for at least 6 months and 129 patients were treated for one year or more.

In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well tolerated in both healthy adult subjects and patients with ESKD.

👍️0

resx18 12月前

Phase 3–ready oral anticoagulant being developed by Cadrenal – as a potential alternative to warfarin to address the current unmet need in this patient population. Tecarfarin is designed to provide more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin. Its unique metabolism via a single enzyme (CES2) may reduce the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events.

👍️0

resx18 12月前

This partnership not only validates tecarfarin’s clinical promise but also strengthens CVKD’s credibility in the industry, making it a compelling watch for investors.

👍️0

Cameo Brien 12月前

Fast Track Designation by FDA
Tecarfarin has received Fast Track status, streamlining regulatory interactions and potentially accelerating approval timelines.

👍️0

resx18 12月前

March 2025, CVKD secured a pivotal collaboration agreement with Abbott (NYSE: ABT) to support its Phase 3 TECH-LVAD trial for tecarfarin. Abbott’s expertise with the HeartMate 3™ device will enhance trial design, site identification, and awareness, reinforcing the critical need for a safer anticoagulant for left ventricular assist device (LVAD) patients. This partnership not only validates tecarfarin’s clinical promise but also strengthens CVKD’s credibility in the industry, making it a compelling watch for investors.

Squeeze em
Short Interest Opportunities: Elevated short interest could set the stage for a short squeeze, especially if bullish sentiment continues to build.

👍️0

resx18 12月前

Tecarfarin’s unique single-enzyme (CES2) metabolism addresses warfarin’s limitations, reducing bleeding risks and drug interactions. Guidehouse research highlights the economic burden of LVAD patients, with major bleeding events costing up to $54,100 per hospitalization. With the LVAD market projected to nearly double by 2032, tecarfarin’s Orphan Drug Designation (ODD) for LVADs and end-stage kidney disease with atrial fibrillation (ESKD+AFib), plus fast-track status, enhances its commercial potential. The collaboration with Abbott (NYSE: ABT) for the Phase 3 TECH-LVAD trial validates tecarfarin’s promise, leveraging Abbott’s HeartMate 3™ expertise to streamline trial execution.

👍 1

resx18 12月前

Technical Indicators ----> Huge (NASDAQ: CVKD) Breakout...

Cadrenal Therapeutics (NASDAQ: CVKD) offers a compelling investment case for those seeking exposure to innovative biopharmaceuticals in the cardiovascular space. Its lead candidate, tecarfarin, a novel anticoagulant, targets significant unmet needs in left ventricular assist device (LVAD) patients and other high-risk cardiovascular conditions.

👍 1

Cameo Brien 12月前

Insider Confidence: Recent insider purchases suggest management’s strong belief in the company’s long-term value and clinical strategy.

👍️0

Cameo Brien 12月前

AI and Robotics Focus: The company’s emphasis on cutting-edge AI and robotics technology aligns with high-growth sectors, drawing investor attention amid rising tech demand.

👍️0

resx18 12月前

Cadrenal Therapeutics Inc. is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, more effective chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds, and deaths than warfarin, the most commonly used anticoagulant for these patients, despite its prevalent adverse events, drug-to-drug interactions, and frequent dosing changes. Cadrenal is focused on evaluating tecarfarin's superiority to warfarin in these patients where DOACs are not recommended in the treatment guidelines of leading cardiology associations. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted LVADs as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is opportunistically planning pivotal clinical trials and pursuing clinical and commercial partnerships to advance tecarfarin. The company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties.

Strong Clinical Pipeline: CVKD is advancing neflamapimod, an oral therapy targeting p38 alpha kinase, with promising data in dementia with Lewy bodies (DLB)—a condition with no FDA-approved treatments.

"Despite decades of use, warfarin has significant limitations – especially in complex patients with LVADs," said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. "This research reinforces our conviction that tecarfarin has the potential to transform anticoagulation management for this high-risk population who currently has no alternative options." https://finance.yahoo.com/news/cadrenal-therapeutics-highlights-research-anticoagulation-120000058.html $CVKD

👍️ 1

Trooperstocks 12月前

$CVKD *FDA* -Orphan Drug & Fast Track Designations: Tecarfarin has received Orphan Drug designation for heart failure patients with LVADs, as well as both Orphan Drug and Fast Track status for ESKD patients with AFib, highlighting its potential to address significant unmet medical needs. #HugePotential #Partnership with $ABT. #LessSideEffects https://preview.redd.it/cvkd-fda-orphan-drug-fast-track-designations-tecarfarin-has-v0-c9ptrgchp9af1.png?width=640&crop=smart&auto=webp&s=84a4be00db52a83e95f0379dc03618cadb1faead

👍️ 1 😎 1

Trooperstocks 12月前

$CVKD $13.47 Offer Up Pre-market! Tecarfarin aims to address critical unmet needs in patients who require chronic anticoagulation. Cadrenal Therapeutics (CVKD)Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) a late-stage biopharmaceutical company dedicated to developing innovative solutions for patients with rare and underserved cardiovascular conditions. Their primary focus is on advancing tecarfarin, a novel oral Vitamin K antagonist (VKA) anticoagulant designed to be a superior and safer alternative to traditional options like warfarin. Addressing Unmet Needs in Anticoagulation. https://www.cadrenal.com/investors/

👍️0

Trooperstocks 1年前

$CVKD pipeline for Tecarfarin:
https://cadrenal.com/pipeline/

👍️ 1 😍 1 😎 1

Trooperstocks 1年前

$CVKD $13.16 +26.05% Pre-Market on good volume! #Bullish

👍️ 1 😎 1

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Cadrenal Therapeutics Inc (CVKD)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

Cadrenal Therapeutics Inc (CVKD) ニュース

Form 8-K - Current report

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Form 8-K - Current report

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Form 8-K - Current report

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Form 8-K - Current report

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

CVKD Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Cadrenal Therapeutics Inc (CVKD)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

Cadrenal Therapeutics Inc (CVKD) ニュース

Form 8-K - Current report

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Form 8-K - Current report

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Form 8-K - Current report

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Form 8-K - Current report

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

CVKD Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する